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Prostate cancerCholesterol has been shown to promote cell proliferation/migration in many cells; however the mechanism(s)
have not yet been fully identiﬁed. Here we demonstrate that cholesterol increases Ca2+ entry via the TRPM7
channel, which promoted proliferation of prostate cells by inducing the activation of the AKT and/or the ERK
pathway. Additionally, cholesterol mediated Ca2+ entry induced calpain activity that showed a decrease in E-
cadherin expression, which together could lead to migration of prostate cancer cells. An overexpression of
TRPM7 signiﬁcantly facilitated cholesterol dependent Ca2+ entry, cell proliferation and tumor growth.Whereas,
TRPM7 silencing or inhibition of cholesterol synthesis by statin showed a signiﬁcant decrease in cholesterol-
mediated activation of TRPM7, cell proliferation, andmigration of prostate cancer cells. Consistent with these re-
sults, statin intake was inversely correlated with prostate cancer patients and increase in TRPM7 expression was
observed in samples obtained from prostate cancer patients. Altogether, we provide evidence that cholesterol-
mediated activation of TRPM7 is important for prostate cancer and have identiﬁed that TRPM7 could be essential
for initiation and/or progression of prostate cancer.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Prostate cancer (PCa) is one of the most common malignancies and
the second leading cause of cancer-related death in men [1–4]. Recent
studies have shown that cholesterol is an emerging clinically relevant
therapeutic target in PCapatients [5]. Importantly, high circulating choles-
terol levels have been shown to increase the risk of overall aggressive PCa
[5,6]. Consistent with these reports, recent clinical data also showed less
aggressive PCa in men taking statins after prostatectomy [7]. Further-
more, an intake of statins also reduced the incidences of PCa treatment
failure for patients undergoing radiotherapy [8]; however, the mecha-
nism as how cholesterol promotes PCa is still poorly understood. Early
stages of PCa growth depend on androgen which also regulates Ca2+
entry [9–11], thus, it is very likely that Ca2+ channelswill play an essential
role in the cellular proliferation and development of PCa [12]. Additional-
ly, cholesterol has been shown to regulate various ion channels [13–15];
however the Ca2+ channel(s) involved in cholesterol induced prolifera-
tion in prostate cells is not yet identiﬁed. Hence, understanding the rolences, School of Medicine and
, ND 58201, USA. Tel.: +1 701
. This is an open access article underof Ca2+ channels that are regulated by cholesterol and induces cell prolif-
eration and/or migration may lead to a better therapeutic target for PCa.
Melastatin-like transient receptor potential (TRPM) subfamilies are a
diverse group of voltage-independent Ca2+-permeable cation channels
that are expressed in mammalian cells [16]. One of its members, TRPM7
channels is widely expressed and recently has been shown to be associat-
ed with cell survival [17,18]. Importantly, TRPM7 has been shown to be
required for increased proliferation and migration in several cancers
such as breast, pancreatic, gastric, and nasopharyngeal cancers [18–20];
but its role in PCa has not yet been identiﬁed even though TRPM7 has
been detected in rat prostate tissues [21]. TRPM7 is aMg2+ and Ca2+per-
meable ion channel that maintains the cellular Ca2+ and Mg2+ homeo-
stasis [22]. In addition, Mg2+ is important for various physiological
functions, further emphasizing the role of TRPM7 channels in cellular de-
velopment. Although along with cell survival TRPM7 has been shown to
regulate Ca2+ and Mg2+ homeostasis [23], the factors that activate and/
or regulate TRPM7 expression that can induce cell survival/proliferation
have not yet been identiﬁed. Importantly, TRPM7 knockout mice are em-
bryonically lethal and targeted disruption of TRPM7 in T cell lineage
disrupted thymopoiesis [24]; further suggesting that these channels are
essential for cellular development and abnormal activation of these chan-
nels can lead to diseases such as cancer. Our previous studies suggest that
TRPM7 is important in prostate cells and maintains cellular Ca2+ and
Mg2+ homeostasis. Furthermore, we have shown that alterations in
Ca2+ to Mg2+ ratio could be essential for the initiation/progression ofthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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channels that initiate Ca2+ entry, which not only facilitates TRPM7 ex-
pression, but also was essential for promoting cell proliferation and mi-
gration of prostate cancer cells. Finally, an inhibition of cholesterol-
induced TRPM7 activation by statins or TRPM7 silencing decreased
Ca2+ entry, cell proliferation and tumor growth. Consistentwith these re-
sults, TRPM7expressionwas increased in PCa samples andmenwhoused
statins showed a decreased incidence of PCa in a retrospective pilot study.
Overall, our results indicate that cholesterol-induced activation of TRPM7
increases cytosolic Ca2+ levels, which activate the AKT/ERK pathway and
calpain activity that together induces cell proliferation and migration in
prostate cancer cells.
2. Materials and methods
2.1. Cell culture reagents and transfection
Control prostate cell line RWPE1 (CRL 11609), prostate cancer cell
line DU145 (HTB-81) and LNCaP (CRL 1740) cells were obtained fromA B
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Fig. 1.Acute cholesterol treatment increases intracellular Ca2+ in prostate cells: (A) Ca2+ imagingw
cells. Analog plots of the ﬂuorescence ratio (340/380) from an average of 40 to 60 cells are show
(p b 0.05) versus RWPE control.Δ indicates signiﬁcance (p b 0.05) versus DU145 control. (C) C
μM2-APB treatment DU145 cells. Analog plots of the ﬂuorescence ratio (340/380) from an aver
380). * and ** indicate signiﬁcance (p b 0.05, p b 0.01) versus control. (E) Application cholestero
under conditions control and cholesterol treatment are shown in (F). Magniﬁcation under the
under these conditions is shown in (G). (H) Application of MgATP in pipette abolish the TRPM
AKT, total ERK and loading control β-actin (except, total AKT 1/2/3 (H-136) from Santa Cruz Bi
treatment of 200 μM cholesterol for 15 min in the presence of calcium, in the presence of 5 mthe American Type Culture Collection (Manassas, VA). Cells were cul-
tured in their respective medium along with various supplements as
suggested by ATCC. Cells were maintained at 37 °C with 95% humidiﬁed
air and 5% CO2 and were passaged as needed. Culture medium was
changed twice weekly and cells were maintained in complete media,
until reaching 90% conﬂuence. For transfection experiments shRNA plas-
mid that targets the coding sequence of human TRPM7 was obtained
from Origene and TRPM7cDNA construct was used. Cells were
transfected with individual shRNA (against TRPM7 or non-target
shRNA (Sigma) (50 nM) or TRPM7plasmid (50 nM) using Lipofectamine
2000 in Opti-MEM medium as per supplier's instructions (Invitrogen))
and assayed after 48 h. Antibodies that were used in this study are de-
scribed in the ﬁgures. All other reagents used were of molecular biology
grade obtained from Sigma chemicals unless mentioned otherwise.
2.2. Soft agar colony formation and cell migration assays
Ten thousand cells were grown in a semisolid agar media in 96-well
plate for 5 days and later solubilized, lysed and detected by the CyQuant0 100 200 300 400 5000.10
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as performed in the absence and in the presence of cholesterol (1 μM) in RWPE1 andDU145
n. (B) Quantiﬁcation (mean± SD) of ﬂuorescence ratio (340/380). * indicates signiﬁcance
a2+ imaging was performed in control, in the presence of cholesterol (1 μM) and plus 500
age of 40 to 60 cells are shown. (D) Quantiﬁcation (mean± SD) of ﬂuorescence ratio (340/
l in bath solution slightly facilitated TRPM7-like currents in DU145 cells. Average IV curves
se conditions is shown as inset. Average (8–10 recordings) current intensity at−100 mV
7-like currents. . (I, J, K) Western blot images showing the expression of pAKT, pERK, total
otechnology, all antibodies were from Cell Signaling, Inc.) in RWPE1 and DU145 cells with
M calcium chelator, EGTA and in the presence of calcium free HBSS buffer, respectively.
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cording to the manufacturer's instructions (CytoSelect 96-well cell
transformation assay-Cell Biolabs, Inc., USA). Images were taken using
the Nikon E5000 Coolpix prior to solubilizing. For cell migration assays
cells were grown on a 12-well plate until 95% conﬂuence and 1 μg/ml
of mitomycin C was added to inhibit further proliferation of cells. The
cell monolayer was scratched using a 200 μl pipette tip and images
were taken using an Olympus CKX41 microscope with QCapture x64
software (Surrey, Canada) immediately after the scratch, marked as 0 h
and after 24 h.2.3. Calpain activation assay
Two million cells were grown on 35-mm plates and the cells were
treated with 1 μM cholesterol for 24 h. The cells were lysed and super-
natantwas used for themeasurement of protein concentration. The cell
lysate was diluted using extraction buffer and the activation was mea-
sured according to the manufacturer's instructions (Abcam, MA). TheA                                            B C
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Fig. 2. Cholesterol facilitates TRPM7 channel function in prostate cells: (A) Representative trac
pletion of intracellular Mg2+ under various conditions (control and 1 μM cholesterol treatmen
(bottom curve) were measured at−100 mV. Average IV curves (developed from maximum
under similar conditions from DU145 to LNCap cells are shown. Outward currents were again
line). Respective IV curve of these cells under these conditions is shown in (D) and (F). (G)
these conditions are shown. * indicates signiﬁcance (p b 0.05) versus untreated cells. (I) Represe
of 500 μM2-APBwas applied followed by the recovery of the current afterwashing of 2-APB. (J)
ERK and loading control β-actin in RWPE1 and DU145 cells with treatment of 200 μMcholester
of TRPM7 in both RWPE1 (1.0±0.18 and1.93±0.09 for control and cholesterol treated RWPE1
cholesterol treated DU145 cells, respectively; p b 0.05: N = 4) cells.samples were analyzed at an excitation of 400 nm and emission at
505 nm using a Multiskan spectrum ﬂuorometer (Thermo labsystems)
and the colorimetric reading was normalized with the respective total
protein concentrations.2.4. Cell proliferation and viability assays
The ten thousand cells were plated in a 96-well plate and synchro-
nized by stimulating with 10% FBS. Then pulsed with BrdU for 2 h
before BrdU incorporation was measured as per manufacturer's instruc-
tions (Roche). For viability assays, cells were seeded on a 96-well plate
at a density of 0.5 × 105 cells/well. The cultures were grown for 24 h
followed by an addition of fresh medium prior to the experiment. Cell
viability was measured by using the trypan blue staining method. Cells
(5 × 106 cells/well) were grown under different conditions for 48 h,
trypsinized, stained using equal volume of trypan blue and counted
using a light microscope. Cell viability was expressed as a percentage of
the control culture.D
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Cells were incubatedwith 2 μMFura-2 (Molecular Probes) for 45min,
washed twice with a Ca2+ free SES (Standard External Solution, include:
10 mMHEPES, 120 mM NaCl, 5.4 mM KCl, 1 mMMgCl2, 10 mM glucose,
pH7.4) buffer. Forﬂuorescencemeasurements, theﬂuorescence intensity
of Fura-2-loaded control cells was monitored with a CCD camera-based
imaging system (Compix)mounted on an Olympus XL70 invertedmicro-
scope equipped with an Olympus 40× (1.3 NA) objective. A
monochrometer dual wavelength enabled alternative excitation at 340
and 380 nm, whereas the emission ﬂuorescence was monitored at
510 nm with an Okra Imaging camera (Hamamatsu, Japan). The images
of multiple cells collected at each excitation wavelength were processed
using the C imaging, PCI software (Compix Inc., Cranbery, PA), to provide
ratios of Fura-2 ﬂuorescence from excitation at 340 nm to that from exci-
tation at 380 nm (F340/F380). Fluorescence traces shown represent
[Ca2+]i values that averages from at least 30 to 40 cells and are a repre-
sentative of results obtained in at least 3–4 individual experiments.
2.6. Electrophysiology
For patch clamp experiments, coverslips with cells were transferred
to the recording chamber and perfused with an external Ringer's
solution of the following composition (mM): NaCl, 145; CsCl, 5;
MgCl2, 1; CaCl2, 1; Hepes, 10; Glucose, 10; and pH 7.3 (NaOH). Whole
cell currentswere recorded using anAxopatch200B (Axon Instruments,
Inc.). The patch pipette had resistances between 3 and 5MΩ after ﬁlling
with the standard intracellular solution that contained the following
(mM): cesium methane sulfonate, 150; NaCl, 8; Hepes, 10; EGTA, 10;
and pH 7.2 (CsOH). With a holding potential 0 mV, voltage ramps rang-
ing from−100mV to+100mV and 100ms durationwere delivered at
2 s intervals after whole cell conﬁguration was formed. Currents were
recorded at 2 kHz and digitized at 5–8 kHz. pClamp 10.1 software was
used for data acquisition and analysis. Basal leak were subtracted from
the ﬁnal currents and average currents are shown. All experiments
were carried out under a room temperature.
2.7. Membrane preparations and Western blot analyses
Cells were harvested and stored at−80 °C. Crude lysates were pre-
pared from RWPE1, DU145, and LNCaP cells as described previously in
[53]. Protein concentrations were determined, using the Bradford re-
agent (Bio-Rad), and 25–50 ug of proteins were resolved on 3–8%
SDS-Tris-acetate gels, transferred to PVDF membranes and probed
with respective antibodies. A 1:500 for TRPM7 (Epitomics, CA), 1:1000
for ERK, pERK, E-cadherin (Cell signaling, MA), and 1:1000 for AKT,
pAKT, and actin (Santa Cruz, CA) antibodies were used to probe respec-
tive proteins. Peroxidase conjugated respective secondary antibodies
were used to label the proteins. The proteins were detected by an en-
hanced chemiluminescence detection kit (SuperSignal West Pico;
Pierce). Densitometric analysis was performed using image J analysis
and results were corrected for protein loading by normalization for β-
actin expression as described in [53–56].
2.8. A pilot hospital-based case–control study
We conducted a pilot case–control study at a community hospital in
Grand Forks, ND, USA, to assess the association between statin use and
PCa. Cases were men with newly diagnosed, histologically conﬁrmed
PCa. Controls were men without clinical cancer who were seen at the
same hospital for an annual physical exam. The study was approved
by the Institutional Review Boards of the hospital and the university.
2.8.1. Immunohistochemistry and imaging
Parafﬁn embedded tissues from age-matched control and adenocar-
cinoma (Gleason score 3 + 4) were obtained and 10 μm thickcryosections were performed. Hematoxylin and eosin (H&E) staining
was performed on the sections using a standard procedure (Sigma, St.
Louis, MO). For immunolabeling respective samples were perme-
abilized at a room temperature with 0.1% TritonX-100 in PBS (pH 7.4),
blocked (10% donkey serum and 5% BSA in PBS), and probed overnight
with TRPM7 primary antibodies in a hydrated chamber maintained at
4 °C. Following incubation with primary antibodies the slides were
washed and processed for DAB staining. Images were acquired at 20
or 40× magniﬁcations and total DAB staining from each section was
quantiﬁed using the image J program.
2.9. Statistical analysis
Mean and standard deviation values were computed for all continu-
ous variables and frequency distributions were calculated for all categor-
ical variables. We compared patients who had statins prescribed in their
charts to patients who did not have such prescription on demographic
and clinical variables using Wilcoxon signed-rank test for non-normally
distributed or t-test for normally distributed continuous variables and
chi-square for categorical variables. All statistical tests were two-tailed
with p b 0.05 considered to be signiﬁcant. Statistics were performed
using SAS (SAS Institute, Cary, NC; Version 9.3 Users Guide).
3. Results
3.1. Acute cholesterol treatment increases intracellular Ca2+ concentration
in prostate cells
Ca2+ plays a vital role in regulating various kinases which are in-
volved inmany cellular processes such as proliferation, migration, inva-
sion,motility, gene transcription and apoptosis [26,27]. Acute treatment
of cholesterol (1 μM) enhanced intracellular Ca2+ levels as shown in
Fig. 1A and B. Importantly, cholesterol effects were much more promi-
nent in prostate cancer cells than in control RWPE1 cells and signiﬁcant
increase in intracellular Ca2+ levels was observed in cancer cells. Fur-
thermore, cholesterol-mediated increase in Ca2+ inﬂux in DU145 cells
was signiﬁcantly inhibited by 2APB, a known Ca2+ channel inhibitor
(Fig. 1C, D). To understand the ion channel(s) responsible for
cholesterol-mediated increase in Ca2+ entry, current recordings
(whole cell) were performed in both control and cancer cells. Impor-
tantly, an inward current (that reversed around zeromV)was observed
in both control RWPE1 andDU145 cells and the application of cholester-
ol in bath solution showed an increase in inward Ca2+ currents both in
control RWPE1 (data not shown) and in DU145 cells (Fig. 1E–G), which
was similar as observed in MagNuM currents [19,32]. To identify the
pharmacological properties of these currents, we next studied the ef-
fects of 2-APB andMg-ATP on these cells.Mg-ATP has been shown to in-
hibit theseMagNuMcurrents, whereas 2-APB has been shown to inhibit
TRPM7 function, but potentiates TRPM6 function [19,32], that also
shows similar electrophysiological properties. Addition of MgATP or
2APB inhibited the currents (Fig. 1H, S1A–H) and addition of cholesterol
did not increase the current intensity. Also, the current properties were
consistent with the previous recording performed in other cells, which
have been shown to be linked with TRPM7 channels [25,28–31]. Addi-
tionally, this cholesterol-mediated enhanced intracellular Ca2+ resulted
in an increase in the phosphorylation of AKT and ERK both in RWPE1
and DU145 cells, which was inhibited by either in addition of 5 mM ex-
ternal EGTA or in the absence of external Ca2+ (Fig. 1I–K; S1I), further
suggesting that Ca2+ entry upon cholesterol stimulation is needed for
their activation.
3.2. Prolonged cholesterol treatment facilitates TRPM7 channel function in
prostate cells
Pathological conditions occur mostly due to chronic exposure of
cholesterol. Therefore, we examined the effect of prolonged (chronic)
1843Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 1839–1850cholesterol treatment in prostate cancer cells. We show here
that prolonged (24 h) cholesterol treatment signiﬁcantly increase
TRPM7 activity (Fig. 2 A–I). The currents facilitated upon cholesterol
treatment were signiﬁcantly increased in both normal prostate and
prostate cancerous cells (in RWPE1, +100 mV was 21.29 ± 1.51 pA/
pF, whereas 28.18 ± 1.73 pA/pF was observed with cholesterol treat-
ment) (Fig. 2A, B). In DU145 and LNCaP, +100 mV was 34.42 ± 2.04
pA/pF and 31.16 ± 2.86 pA/pF in control, whereas 44.12 ± 3.01 pA/pF
and 39.73 ± 3.32 pA/pF were observed in cholesterol treated
cells (Fig. 2C–I). Importantly, the inward currentswere also signiﬁcantly
facilitated in cancerous cells (For DU145 and LNCaP, −100 mV
was −0.59 ± 0.13 pA/pF and −0.92 ± 0.18 pA/pF in unstimulated
conditions, whereas −1.82 ± 0.25 pA/pF and −1.72 ± 0.12 pA/pF
were observed in cholesterol treated cells). However, no signiﬁcant
difference in normal prostate RWPE1 cells was observed upon choles-
terol treatment (−100 mV was 0.45 ± 0.22 pA/pF in control, whereas
0.75 ± 0.42 pA/pF upon cholesterol treatment) (Fig. 2H). Furthermore,
extracellular addition of 500 μM of 2-APB, dramatically decreased cur-
rent amplitude which was able to recover after wash-out of 2APB sug-
gesting that indeed these currents are mediated via TRPM7 (Fig. 2I).
Additionally, cholesterol-dependent increase in the phosphorylation
of AKT and ERK was inhibited in cells treated with 2APB (Fig. 2J).
Furthermore prolonged cholesterol treatment showed an increase in
TRPM7 expression in both RWPE1 and DU145 cells (Fig. 2K).
Overall, these results suggest that cholesterol treatments potentiates
TRPM7 currents and this increase in intracellular Ca2+ levels
could also regulate TRPM7 expression via the activation of the ERK
pathway.DU145 RWPE
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Fig. 3.Cholesterol-mediated activation of TRPM7 regulates cellular function inprostate cells: Cel
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incorporation. Each bar gives the mean ± SEM of 4 separate experiments. **, p b 0.01, ***, p
cells andDU-145 cells treatedwith 1 μMcholesterol. Imageswere taken after thewound scratch
activitymeasured using calpain activity kit fromAbcam, inRWPE1 andDU145 cells and after tre
cells treated with 1 μM cholesterol for 24 h). Each bar gives the mean ± SEM (N= 4, ***, p b 0
Signaling Technology) in both RWPE1 (1.0±0.23 and0.63±0.18 for control and cholesterol tre
control and cholesterol treatedDU145 cells, respectively;p b 0.05: N=4). (G) 10 μMPD98059 (E
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respectively; p b 0.05, N = 4) cells. (H) 50 μM 2APB treatment for 24 h decreased the express
cells, respectively; p b 0.01, N = 3) and RWPE1 (1.3 ± 0.27 and 0.40 ± 0.051 for control and tr3.3. TRPM7 activation by cholesterol promotes cell proliferation in prostate
cells
Cholesterol is an essential membrane component of animal cells,
which makes up about one-third of the lipid content of the plasma
membrane [5]. Therefore the effect of prolong cholesterol treatment
on TRPM7 expression along with other cellular functions was studied
in prostate cells. Prolonged cholesterol treatment also increased cell vi-
ability in both RWPE1 and DU145 cells (Fig. 3A). Consistent with this
observation cellular proliferation was also increased as deﬁned by
using BrdU incorporation assay in RWPE1, androgen independent
DU145, and androgen dependent LNCaP cells (Fig. 3B), which was
again signiﬁcantly higher in prostate cancer cells. To further understand
the signiﬁcance of cholesterol, cells were treated with 1 μM cholesterol
and cell migration was studied after 24 h. As shown in Fig. 3C and S1J,
increased migration of RWPE-1, DU145 and LNCaP cells was observed
in cholesterol treated cells, which was inhibited in the presence of
2APB (data not shown). Increased migration of cells under cholesterol
treatment might have resulted from increased activity of calpain that
are also Ca2+ dependent [33,34]. Thus, calpain activity was measured,
which showed a signiﬁcant increase in calpain activity in cells incubated
with cholesterol (Fig. 3D). Calpain-dependent proteolysis of E-cadherin
is known to be associated with prostate cancer [35], hence we next
studied the cholesterol mediated E–cadherin expression in RWPE1
and DU-145 cells which was down-regulated in the presence of choles-
terol (Fig. 3E). Since, cholesterol treatment increases ERK phosphoryla-
tion, and showed increase in TRPM7 expression, we thus studied
whether TRPM7 expression is dependent on Ca2+-induced activation1
TRPM7
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.001. (F) 1 μM Cholesterol treatment for 24 h decreases the expression of E cadherin (Cell
atedRWPE1 cells, respectively;p b 0.05, N=4) andDU145 (1.0±0.05 and0.46±0.21 for
RK inhibitor) treatment for 24 h decreased the expression of TRPM7 in bothDU145 (0.98±
3) and RWPE1 (1.2 ± 0.27 and 0.51 ± 0.11 for control and PD98059 treated RWPE1 cells,
ion of TRPM7 in both DU145 (1.0 ± 0.07 and 0.60 ± 0.03 for control and treated DU145
eated RWPE1 cells, respectively; p b 0.05: N = 4) cells.
1844 Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 1839–1850of ERK. Importantly, cells treated with ERK inhibitor PD98059 (10 μM
for 24 h) decreased TRPM7 expression in both cells (Fig. 3F). Important-
ly, 2APB also reduced TRPM7 expression when cells were incubated
with 50 μM 2APB for 24 h (Fig. 3G), suggesting that the expression of
TRPM7 is dependent on Ca2+-dependent activation of ERK.
3.4. Cholesterol mediated increase in Ca2+ entry and cell proliferation of
prostate cells is dependent on TRPM7 expression
To further establish that the effect of cholesterol in cell proliferation
and migration was dependent on TRPM7 expression, we silenced
TRPM7 and evaluated the effect of cholesterol on prostate cells. As
shown in Fig. 4A and in Supplementary Fig. 2, expression of shTRPM7
(shTRPM7), but not the non-targeting shRNA, in prostate cells showedE F                                        G
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TRPM7-like currents, which average IV curves (developed frommaximumcurrents) under vario
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versus untreated cells.a decrease in TRPM7 expression. Control actin levels were however
not changed under these conditions. Importantly, cholesterol-induced
Ca2+ inﬂuxwas also inhibited in both control RWPE1 and prostate can-
cer DU145 cells that was expressing shTRPM7 (Fig. 4B–D). Consistent
with these results, TRPM7 currents were also signiﬁcantly inhibited in
both control and prostate cancer cells (DU145 and LNCaP) that express
shTRPM7 (Fig. 4E–J and S2B, D, E). Additionally, cholesterol treatment
showed no increase in TRPM7 currents in cells expressing shTRPM7
(Fig. 4E–J); further showing that cholesterol activates TRPM7 currents.
More importantly, consistentwith these results, cholesterol-induced in-
crease in cell survival and cell proliferation of control or prostate cancer
cells was also inhibited in cells treated with shTRPM7 (Fig. 5A, B; S2G).
Additionally, cholesterol-dependent increase in the phosphorylation of
AKT and ERK was inhibited in cells expressing shTRPM7 (Fig. 5C and               H    
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1845Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 1839–1850D). In contrast control shRNA expressing DU145 cells showed a signiﬁ-
cant increase in AKT and ERK phosphorylation (5C, D). Similar data was
also observedwith RWPE1,where control shRNA showed an increase in
cholesterol-mediated activation of AKT and ERK (data not shown),
whereas cells expressing TRPM7shRNA had no increase in AKT or ERK
phosphorylation (5C). Calpain activity upon cholesterol activation was
also inhibited in prostate cancer DU145 cells that was expressing
shTRPM7 (Fig. 5E). Finally, the tumor growth was also reduced in
shTRPM7 cells, studied using soft agar colony formation assays in both
DU145 and LNCaP cells (Fig. 5F, G, S2G, H). These results strongly sug-
gest that TRPM7 expression in prostate cancerous cells plays an impor-
tant role in cholesterol-mediated increase in cytosolic Ca2+ that is
essential for increase in cell proliferation/survival and migration, there-
fore may be critical for the initiation and or progression of PCa.3.5. Overexpression of TRPM7 enhances cholesterol-mediated effects in
prostate cancer cells
To understand the signiﬁcance of TRPM7 in cholesterol-mediated
activation, cells were transfected with TRPM7. Western blot images
conﬁrm the overexpression of TRPM7 in DU145 cells (Fig. 6A) and
LNCaP cells (Fig. S2A). Furthermore, the overexpression of TRPM7
showed a signiﬁcant increase in MagNuM currents in both DU145
cells and LNCaP cells (Fig. 6B–E and S2B). Additionally, cholesterolA B
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indicates values that are signiﬁcantly different from untreated cells p b 0.05. (B). Bar diagram
targeting marked as shC and TRPM7 knockdown cells marked as shTRPM7) cells after BrDU in
icance p b 0.05. (C)Western blot images showing the expression of pAKT, pERK, total AKT (AKT
and DU145 cells with treatment of 200 μM cholesterol for 15 min. Panel on the right show
representing the densitometry reading showing the activity of phospho form of AKT and ERK
pAKTorpERKnormalizedwith the total AKT or ERKexpression of the respective samples. Eachb
measuredusing calpain activity kit fromAbcam, inDU145 (shRNA controlmarkedas shC andTR
for 24 h (marked as none treated as control and Chol 1 μM for cells treatedwith 1 μM cholestero
the soft agar colony tumor growth in DU145 cells and TRPM7 knockdown cells. Bar diagram
knockdown DU145 cells after agar media being solubilized, lysed and detected by the patentedtreatment showed a further increase in TRPM7 currents in cells overex-
pressing TRPM7 (Fig. 6C–E and S.2B). TRPM7 overexpression also en-
hanced cholesterol-induced cell proliferation of prostate cancer cells
(Fig. 6F and S2F). The overexpression of TRPM7 in both DU145 cells
and LNCaP also resulted in an increase tumor growth, studied using
soft agar colony formation assay (Fig. 6G and S2G, H). Finally, cholester-
ol levels were found to be signiﬁcantly increased in prostate cancer cells
(DU145, and LNCaP), when compared with control RWPE1 cells
(Fig. S2I), further suggesting that cholesterol mediated activation of
TRPM7 cells is perhaps critical for cancer cell growth. Consistent with
these results increased TRPM7 expression was observed in samples ob-
tained from adenocarcinoma patients when compared with age-
matched control samples (Fig. 6H). These results further suggest that
TRPM7 expression could lead to prostate cancer.3.6. Statins attenuate cholesterol mediated activation of TRPM7 channel in
prostate cells
Statins inhibit themevalonate pathway, thereby preventing the syn-
thesis of cholesterol [36]. Use of statin has been shown to relate to PCa
outcomes [37], but the mechanism(s) is not known. We thus used two
statin drugs (simvastatin and mevastatin) to examine if they block
cholesterol-mediated activation of TRPM7 that induces cell proliferation
in prostate cells. Statin treatment inhibited Ca2+ inﬂux in a doseD
U-
14
5
shC shTRPM7
pAKT
C RWPE1 DU145
AKT
ERK
Actin
shTRPM7
pERK pERK
shC
AKT
ERK
Actin
DU145
pAKT
G
F
iability under cholesterol treated conditions in RWPE1 and DU145 cells is shown in (A). *
showing the relative absorbance at 450 nm of RWPE1 and DU145 (shRNA control non-
corporation. Each bar gives the mean ± SEM of 4 separate experiments. * indicates signif-
1/2/3 (H-136), ERK and loading control β-actin in shTRPM7 (TRPM7 knockdown) RWPE1
s the stimulation of DU145 cells overexpressing control shRNA (shC). (D) Bar diagram
, in shC and shTRPM7 in DU145 cells. Each bar represents the percentage of respective
ar gives themean±SEM(N=4, ***,p b 0.001, NS=non signiﬁcance). (E) Calpain activity
PM7 knockdown cellsmarked as shTRPM7) cells and after treatmentwith 1 μMcholesterol
l for 24 h). Each bar gives themean± SEM (N=4, ***, p b 0.001 (F). Images representing
represents the relative ﬂuorescence reading at 485/525 nm ﬁlters, of control and TRPM7
CyQuant® GR Dye in a ﬂuorescence plate reader.
DU145
TRPM7
Actin
Control + TRPM7
-100 -50 0 50 100
-10
0
10
20
30
40
50
60
pA
/p
F
mV
DU145
 DU145+TRPM7
-100 -50 0 50 100
-10
0
10
20
30
40
50
60
pA
/p
F
mV
DU145
 +TRPM7 
 +TRPM7+CHOL
0
10
20
30
40
50
60
*+100mV
pA
/p
F
0
-1
-2
*
-100mV
pA
/p
F
A B C
D E F
G H Control         Prostate Cancer
TR
PM
7 
H
& 
E 
St
ai
n 
Fig. 6.Overexpression of TRPM7 resulted in enhanced effect in cholesterol induce function: (A) Representative blots indicatingDU145 cells overexpressing TRPM7or control non-targeting
shRNA. Cell lysates fromDU145 cellswere resolved onNuPAGE 3–8% Tris-Acetate gels and analyzed byWestern blotting using TRPM7 antibody (1.0±0.09 and 2.85±0.42 for control and
DU145 TRPM7overexpressed cellsmarked as+M7, respectively;p b 0.05:N=4)β-actinwas used as loading control. InDU145 cells transfectedwith overexpress TRPM7and cholesterol
pretreatment for 24h affect TRPM7-like currents,which average IV curves (developed frommaximumcurrents) under various conditions are shown in (B) and (C). (D), (E) Average (8–10
recordings) current intensity at +100 mV and−100mV under these conditions is shown. * indicates signiﬁcance (p b 0.05) versus untreated cells. (F) bar diagram showing the relative
absorbance at 450 nm of DU145 (shRNA control marked as shC and TRPM7 overexpressed cells marked as +M7) with and without 1 μM cholesterol treatment for 24 h and 2 h of BrDU
incorporation. Each bar gives the mean ± SEM of 4 separate experiments. * indicates signiﬁcance *, p b 0.05, ** p b 0.01 and *** p b 0.001. (G) Images representing the soft agar colony
tumor growth in control DU145 cells and TRPM7overexpressing cells. Bar diagram represents the relativeﬂuorescence reading at 485/525 nmﬁlters, of control and TRPM7overexpressing
DU145 cells after agarmedia being solubilized, lysed anddetectedby thepatentedCyQuant®GRDye in aﬂuorescence plate reader. (H) Expression of TRPM7 in control and prostate cancer
tissues.
1846 Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 1839–1850dependent manner. Pretreatment with simvastatin and mevastatin for
24 h inhibited Ca2+ inﬂux induced by cholesterol in both normal pros-
tate and cancerous cells (Fig. 7A–D). Cancerous prostate cells (DU145)
were however more sensitive to statin treatment than normal RWPE1
prostate cells. Importantly in membrane current recording (TRPM7
function), pretreatment with simvastatin for 24 h inhibited TRPM7 cur-
rents only in cancerous prostate cells, but not in control cells (Fig. 7E–
H). Also mevastatin decreased TRPM7 currents more than simvastatin
indicating that different statins can alter TRPM7 function differently.
Consistent with these results addition of external cholesterol restored
statin-mediated decrease of TRPM7 currents in prostate cells (Fig. 7I–
K). Importantly, Ca2+ inﬂux was not further decreased upon statin
treatment in TRPM7 silenced cells (Fig. S3A-D). Similar results were
also observedwith TRPM7 currents and no signiﬁcant decrease was ob-
served in TRPM7 currents in cells expressing shTRPM7 group and
shTRPM7 treated with statins (Fig. S3E-H), suggesting that the effects
observed above were due to TRPM7. To understand as how statin treat-
ment is able to inhibit cholesterol mediated increase in Ca2+ inﬂux, we
assayed TRPM7 expression in these cells. Importantly, pretreatment
with statins decreased TRPM7 protein expression in both normal andprostate cancerous cells (Fig. 8A). These results again suggest that the
expression of TRPM7 was dependent on cholesterol-mediated Ca2+ in-
ﬂux via TRPM7. Overall, results presented thus far indicate that TRPM7
channel is involved in cholesterol mediated activation of Ca2+ inﬂux
which can be reversed by the pretreatment of statins.
3.7. Statin inhibits cholesterol mediated increase in cell proliferation and
migration in prostate cancer cells
The results presented above suggest that cholesterol increases Ca2+
entry via TRPM7 channels, which is critical for cell proliferation and or
cancer progression, but can be inhibited by statins. Hence we studied
proliferation andmigration of cancer cells in the presence of statins. Im-
portantly, a dominant decrease in cell survival was observed in prostate
cancerous cells in a time dependent manner. Additionally, mevastatin
treatment for 24 h, showed a signiﬁcant decrease in cell proliferation
when compared with simvastatin (Fig. 8B, C). These results are consis-
tent as mevastatin decreased TRPM7 currents more than simvastatin.
To establish if cholesterol treatment can revert the effects of mevastatin
we treated DU145 cells simultaneously with cholesterol along with
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1847Y. Sun et al. / Biochimica et Biophysica Acta 1843 (2014) 1839–1850varying doses of mevastatin. As indicated in Fig. 8C, mevastatin showed
a dose dependent decrease in cell survival and addition of cholesterol
partially rescued cell proliferation in cancer cells. Importantly, choles-
terol was much efﬁcient at higher statin concentration. Consistent
with these results, a dominant inhibition in cell migration was also ob-
served when prostate cancer cells were treated with simvastatin and
mevastatin for 24 h (Fig. 8D). Overall, these results suggest that statin
treatment inhibits TRPM7 expression and function thereby inhibiting
cancer cell proliferation and migration.
3.8. Statin use was inversely associated with PCa
Toﬁnally establish the link between statin use and PCa, records from
PCa and age-matched control patientswere used. Themean agewas not
signiﬁcantly different in both groups (Table 1). Importantly, patients
that used tobacco (1 pack per day) had a signiﬁcantly higher prevalence
of PCa (20% vs. 8%, respectively for control; p= 0.04). This is consistent
as cigarette smoking has been shown to increase cholesterol levels [38,
39]. Median PSA was also lower in PCa patients that took statins; how-
ever no difference in the Gleason score was observed (data not shown).
Importantly, the use of statin showed an inverse correlation,where stat-
in users had signiﬁcantly lower prevalence of newly diagnosed prostate
cancer (78% had no cancer that used statins versus 22% that had cancerand did not used statins) (Table 1). Taken together, these results suggest
that statin treatment could inhibit prostate cancer cell proliferation and
migration, whichwas dependent on TRPM7 function as they can inhibit
TRPM7 function.
4. Discussion
TRPM7 channels are widely expressed in cells including prostate tis-
sues [21].We recently reported that TRPM7 channels were expressed in
both normal (RWPE1) and prostate cancerous cells (DU145, PC3) and
alterations in the Ca2+/Mg2+ ratio facilitated cell proliferation in cancer
cells [12]. Similarly TRPM7 has been shown to be critical for various
other cancers and together our results suggest that TRPM7 can be criti-
cal for PCa initiation and/or progression. However the factors that can
increase TRPM7 expression and function are not known. In the present
study,we found that acute andprolonged cholesterol treatment induces
Ca2+ inﬂux in prostate cells that were dependent on TRPM7 channels.
Moreover, this cholesterol-mediated increase in Ca2+ inﬂux was also
essential for regulating TRPM7 expression which could be a feed for-
ward mechanism that can be activated in prostate cancer cells. Choles-
terol is a key component of the plasma membrane and has been
shown to regulate the function of various ion channels in themembrane
[14,40]; however it is unknown if cholesterol can regulate TRPM7
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Table 1
Demographic, clinical characteristics and prostate cancer status among statin users and none users.
Variables Statin use No statin use p-Value
n % n %
Total (n = 121) 66 55 55 45
Age, mean ± SD 69 ± 7 67 ± 8 .11
Smoking status .006
Current 12 19 7 15
Former 36 56 15 31
Never 16 25 26 54
Prostate-speciﬁc antigen, ng/ml 3.6 (0.1–22.5) 5.7 (0.3–748.1) .003
Gleason scores .77
Low grade (b7) 20 57 26 60
High grade (≥7) 15 43 17 40
Serum albumin, g/dl 3.86 ± 0.4 3.99 ± 0.3 .16
Corrected serum calcium, mg/dla 9.52 ± 0.5 9.39 ± 0.42 .25
Type of statin
Hydrophobic 60 91 –
Hydrophilic 6 9 –
Cancer status .004
No cancer (n = 43) 31 47 12 22
Newly diagnosed prostate cancer (n = 78) 35 53 43 78
Hydrophobic: atorvastatin, lovastatin, and simvastatin.
Hydrophilic: rosuvastatin, and pravastatin.
a Based on 44 and 26 patients for statin users and none users respectively.
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channel is not clear in diseases such as PCa. A recent report has shown
that cholesterol can regulate Ca2+ entry via nonspeciﬁc Ca2+ channels
[41]. Our data speciﬁcally showed that acute and prolong cholesterol
treatment activates TRPM7 channels thereby increasing cytosolic Ca2+
levels that not only increase TRPM7 expression, but also promote cell
proliferation in prostate cancer cells. TRPM7 has been implicated in
the control of cellular proliferation and viability by transporting metal
ions to other cells [29], which is consistent with the results presented
here. Additionally, the inhibition of TRPM7 channel activity has been
shown to decrease proliferation of breast cancerous cells and
hypopharyngeal squamous cell carcinoma cells [42,43], further suggest-
ing that it can have a role in PCa. Importantly higher cholesterol levels as
well as cholesterol-mediated increase in TRPM7 functionwere observed
only in cancerous cells. Similarly, cholesterol can also activate other ion
channels andmore research is needed to fully identify the role of choles-
terol in activating Ca2+ channels. In addition, cholesterol is important
for lipid rafts that have been previously shown to be important for
Ca2+ entry [40,55] thus, there may be additional Ca2+ entry channels
that can also contribute toward this process.
To further understand the role of prolonged cholesterol in PCa, we
found that cholesterol mediated increase in Ca2+ entry facilitated cell
migration in prostate cancerous cells. This increase in migration was
mainly due to the activation of Ca2+-activated calpains, which inhibits
E cadherins expression that could result in the loss of tight junction's
thus inducing cell migration. Epidemiologic studies indicated that cho-
lesterol increases the risk of PCa and cholesterol is shown to regulate
proliferation andmigration in PCa [5,44,45]. Our studies provide further
evidence that this increase of cell proliferation, due to cholesterol de-
pendent increase in Ca2+ inﬂux via TRPM7, was dependent on AKT
and ERK phosphorylation, which is consistent with the previous studies
[36,46]. The previous studies have suggested the role of cholesterol in
PCa [5,44], where patients diagnosed with hyper-cholesterolemia had
higher likelihood for PCa [44]. In agreement with these reports, our re-
sult also implicates that cholesterol plays a critical role in prostate can-
cer cellsmigration and proliferation, whichwas again dependent on the
activation of TRPM7. Thus, our studies not only compliment these previ-
ous studies but also provide the mechanism as to how cholesterol in-
duces PCa.
Epidemiologic data also suggest that cholesterol increases the risk of
PCa [47–50]. Statins are used clinically to reduce LDL levels and they in-
hibit the rate-limiting step in cholesterol synthesis, but their role in PCa
is not fully deﬁned. We found that statins decrease viability and migra-
tion of prostate cancer cells. More importantly, the addition of choles-
terol partially recovered cell viability that was inhibited by statin
treatment. To understand themechanismwe show here that statins re-
duced Ca2+ inﬂux thatwas induced by cholesterol, by inhibiting TRPM7
currents. Furthermore, statins decreased TRPM7 expression, which
could be important for the inhibition of cell migration and cell prolifer-
ation critical for PCa. Evaluating the clinically relevant factors that affect
PCa would not only provide a better understanding on the mechanism
that could alter PCa progression, but could also identify new drug tar-
gets for PCa. Our results further show that TRPM7 expression was in-
creased in samples obtained from PCa patients and individuals that
used statin had a signiﬁcant decrease in the likelihood of developing
PCa. However, these ﬁndings should be interpreted with caution since
this is an observational study using a small sample size. Additionally, al-
though we did not separate the risk reduction with regard to PSA or
Gleason score, it has been previously shown that statin use is greatest
for decreasing the risk of clinically more aggressive disease (Gleason
score b 7) [7]. Together these results suggest that statins not only inhibit
cholesterol levels [51,52], but can also inhibit PCa, by inhibiting TRPM7
function. Although other mechanisms whereby statins may inhibit PCa
are also possible, our results strongly suggest that statin treatment in-
hibits TRPM7 expression and function thereby inhibiting cell prolifera-
tion and migration in PCa.To further deﬁne the role of TRPM7 in cholesterol mediated induc-
tion of prostate cell proliferation, we reciprocally silenced and
overexpressed TRPM7 channels. Importantly in TRPM7 silenced cells
statins were unable to further reduce Ca2+ inﬂux and TRPM7 currents.
Although at present we cannot limit that cholesterol dependent effect
was exclusively due to TRPM7, silencing of TRPM7 was able to inhibit
cholesterol dependent increase in Ca2+ entry as well as cell prolifera-
tion. Consistentwith this overexpression of TRPM7 showed a signiﬁcant
increase in cell proliferation, migration and tumor growth. Additionally,
TRPM7 expressionwas increased in PCa samples. Together these results
establish that TRPM7 channels are involved in PCa. In addition, choles-
terol is an emerging clinically relevant therapeutic target in PCa [5]
and our studies give a new dimension into the role of non-selective
transient receptor potential cation channels which can be inhibited to
prevent PCa (Fig. 7H). However prospective epidemiologic studies are
needed to assess the function of TRPM7 inwet tissue andwhether statin
use impacts serum Ca2+ and Mg2+ that can activate TRPM7.
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